Previous 10 | Next 10 |
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare C...
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with long-term stable disease (SD), and three patients who have now received ther...
Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab Company announces Claudin 18.2 ISAC program with a poster detailing in vitro and in vivo ex...
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: ...
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that updated clinical data from its Phase 1/2 dose-escalation st...
2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
2023-09-28 08:43:44 ET Chico's Fas ( CHS ) +63% soars 63% after landing buyout offer from Sycamore Partners. Gritstone ( GRTS ) +27% . Peloton Interactive ( PTON ) +14% joined forces - analysts don't expect huge upside. Vapotherm (...
2023-09-28 08:28:33 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics For further details see: Bolt Bio spikes on FD...
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers The FDA granted BDC-1001 Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal j...
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...